herpes zoster neuralgia
Conditions
Interventions
Esketamine group:Esketamine 1mg/kg/48h for maintenance.
Sponsors
Department of Pain Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1,Age 18–70 years,Both Male Female. 2. Individuals diagnosed with herpes zoster who have experienced neuropathic pain within the dermatomal distribution for a duration of six months or less. 3. Patients who have taken a total daily dosage of more than two capsules of pregabalin or equivalent medications, and who report a numerical rating scale (NRS) pain score of =4 during the 24 hours preceding hospitalization. 4. Participants must voluntarily sign an informed consent form, comprehend and complete self-assessment scales, and be capable of cooperating in the completion of clinician-assessed forms, as well as complying with the evaluations and follow-up requirements of the clinical trial.
Exclusion criteria
Exclusion criteria: 1.Combined with severe heart, liver, kidney and metabolic diseases, malignant tumors. 2. Individuals requiring long-term administration of hormones or immunosuppressive agents due to hematological disorders, nephrotic syndrome, liver transplantation, kidney transplantation, or bone marrow transplantation. 3. Pregnant or lactating women. 4. Patients with psychiatric disorders. 5. Patients who have previously undergone dorsal root ganglion pulsed radiofrequency treatment at other institutions; those who, after admission, did not undergo dorsal root ganglion pulsed radiofrequency treatment due to infections or other reasons. 6. Patients for whom esketamine is contraindicated or should be used with caution, including those with poorly controlled or untreated hypertension, untreated or inadequately treated hyperthyroidism, and patients with glaucoma. 7. Subjects who have used esketamine or ketamine within the past three months. 8. Individuals currently participating in other clinical studies or receiving treatment with other experimental drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRS(Numerical Rating Scale) score: The NRS scores for the combined application of esketamine in the treatment of postherpetic neuralgia over a 48-hour period.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety and depression symptom scores (HAMA, HAMD-24) were assessed after 48 hours, 1 week, 2 weeks, 1 month, and 3 months of treatment.;Sleep quality of patients (PSQI) at 48 hours, 1 week, 2 weeks, 1 month, and 3 months post-treatment.;The dissociative state scores (CADSS), adverse reactions, and complications during the 48-hour infusion of esketamine.;The expression levels of complete blood count, liver and kidney function indicators, interleukin-6 (IL-6), IL-2, IL-4, tumor necrosis factor-alpha (TNF-a), and interferon-gamma (IFN-?) were measured in patients prior to surgery and one month postoperatively.; | — |
Countries
China
Contacts
Public ContactZhiying Feng
Department of Pain Medicine, College of Medicine,the First Affiliated Hospital, Zhejiang University,79 Qingchun Road, Hangzhou 310003, Zhejiang,China
Outcome results
None listed